Development of a Flow Cytometry Assay to Predict Immune Checkpoint Blockade-Related Complications.
assay validation
biomarker
effector memory T cells
flow cytometry
immune checkpoint inhibition
immune-related adverse events
monocytes
prediction
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
27
08
2021
accepted:
27
10
2021
entrez:
6
12
2021
pubmed:
7
12
2021
medline:
9
2
2022
Statut:
epublish
Résumé
Treatment of advanced melanoma with combined immune checkpoint inhibitor (ICI) therapy is complicated in up to 50% of cases by immune-related adverse events (irAE) that commonly include hepatitis, colitis and skin reactions. We previously reported that pre-therapy expansion of cytomegalovirus (CMV)-reactive CD4
Identifiants
pubmed: 34868015
doi: 10.3389/fimmu.2021.765644
pmc: PMC8637156
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
765644Informations de copyright
Copyright © 2021 Schilling, Glehr, Kapinsky, Ahrens, Riquelme, Cordero, Bitterer, Schlitt, Geissler, Haferkamp, Hutchinson and Kronenberg.
Déclaration de conflit d'intérêts
MK is a Beckman Coulter Life Sciences associate. SH has received consulting fees and speaker’s honoraria from BMS and Merck Sharp & Dohme (MSD). NA is employed by MVZ for Laboratory Medicine Raubling. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Immunother Cancer. 2015 Sep 15;3:39
pubmed: 26380086
Lancet Oncol. 2019 Sep;20(9):1239-1251
pubmed: 31345627
Cancer. 2017 Jun 1;123(S11):2143-2153
pubmed: 28543699
J Exp Med. 2005 Apr 4;201(7):1101-12
pubmed: 15795235
Cancer Res. 2017 Nov 15;77(22):6353-6364
pubmed: 28904066
Oncoimmunology. 2021 Jan 4;10(1):1838140
pubmed: 33489468
J Clin Invest. 2018 Feb 1;128(2):715-720
pubmed: 29309048
Nat Rev Dis Primers. 2020 May 7;6(1):38
pubmed: 32382051
Front Neurol. 2015 Aug 19;6:179
pubmed: 26347708
Nat Commun. 2021 Mar 4;12(1):1439
pubmed: 33664251
Cancer Lett. 2019 Aug 1;456:80-87
pubmed: 31051213
J Transl Med. 2013 Mar 22;11:75
pubmed: 23521917
J Immunol. 2021 Jul 15;207(2):696-708
pubmed: 34261668
J Nucl Cardiol. 2016 Jun;23(3):511-3
pubmed: 25995184
Front Immunol. 2021 Jul 01;12:694055
pubmed: 34276685
Nat Immunol. 2020 Nov;21(11):1346-1358
pubmed: 32868929
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Proc Natl Acad Sci U S A. 2019 Oct 29;116(44):22246-22251
pubmed: 31611368
N Engl J Med. 2016 Nov 03;375(18):1749-1755
pubmed: 27806233
J Immunother Cancer. 2019 Feb 12;7(1):43
pubmed: 30755279
Bioanalysis. 2018 Jun 1;10(12):957-968
pubmed: 29923754
J Natl Compr Canc Netw. 2019 Mar 1;17(3):255-289
pubmed: 30865922
J Clin Invest. 2014 May;124(5):2246-59
pubmed: 24667641
Ann Oncol. 2017 Jun 1;28(6):1368-1379
pubmed: 28368458
J Clin Oncol. 2017 Dec 1;35(34):3807-3814
pubmed: 28841387
N Engl J Med. 2015 May 21;372(21):2006-17
pubmed: 25891304
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580
pubmed: 31092901
Drugs. 2018 Jul;78(11):1085-1103
pubmed: 29961185
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Curr Protoc Cytom. 2017 Jan 5;79:1.3.1-1.3.27
pubmed: 28055116
Methods Mol Biol. 2019;2032:81-104
pubmed: 31522414
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
N Engl J Med. 2018 Jan 11;378(2):158-168
pubmed: 29320654
Br J Cancer. 2019 Jan;120(1):63-68
pubmed: 30377338
Nat Rev Immunol. 2012 Feb 17;12(3):191-200
pubmed: 22343568
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Cell Rep. 2016 Nov 22;17(9):2474-2487
pubmed: 27818087
Sci Transl Med. 2014 Apr 2;6(230):230ra45
pubmed: 24695685
Pharm Res. 2006 Feb;23(2):312-28
pubmed: 16397743
Int J Mol Sci. 2021 Jul 27;22(15):
pubmed: 34360781
J Transl Med. 2018 Apr 2;16(1):82
pubmed: 29606147
Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):11919-11924
pubmed: 27698113
Nat Immunol. 2003 Mar;4(3):225-34
pubmed: 12563257
JAMA Oncol. 2019 Nov 1;5(11):1633-1635
pubmed: 31436791
Nat Immunol. 2005 Aug;6(8):793-9
pubmed: 16025119
Lancet Oncol. 2018 Nov;19(11):1480-1492
pubmed: 30361170
Sci Transl Med. 2016 Mar 2;8(328):328rv4
pubmed: 26936508
Pharm Res. 2005 Apr;22(4):499-511
pubmed: 15846456
Pharm Res. 2009 Dec;26(12):2551-7
pubmed: 19826929